Bio-Behavioral Health — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$675,622	63
2024	Research	$117,329	9
2023	Research	$170,206	12
2022	Research	$117,397	6
2021	Research	$107,963	9

Breakdown

Who paid Research payments · program years 2021–2025

Eisai Inc. $595,887 44 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $583,746 14 payments
Boehringer Ingelheim International GmbH $8,884 41 payments

Studies the money was for Research payments · program years 2021–2025

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $595,887 44 payments
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $588,013 54 payments
Phase II dose finding trial in monotherapy for MDD $4,617 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.